Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (Review)

Kohn AD and Moon RT: Wnt and calcium signaling: β-catenin-independent pathways. Cell Calcium. 38:439–446. 2005.

Deroo BJ and Korach KS: Estrogen receptors and human disease. J Clin Invest. 116:561–570. 2006. View Article : Google Scholar : PubMed/NCBI

Riggins RB, Schrecengost RS, Guerrero MS and Bouton AH: Pathways to tamoxifen resistance. Cancer Lett. 256:1–24. 2007. View Article : Google Scholar : PubMed/NCBI

Mueller SO and Korach KS: Estrogen receptors and endocrine diseases: lessons from estrogen receptor knockout mice. Curr Opin Pharmacol. 1:613–619. 2001. View Article : Google Scholar : PubMed/NCBI

Henderson BE and Feigelson HS: Hormonal carcinogenesis. Carcinogenesis. 21:427–433. 2000. View Article : Google Scholar : PubMed/NCBI

Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S and Gustafsson JA: Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA. 93:5925–5930. 1996. View Article : Google Scholar : PubMed/NCBI

Mosselman S, Polman J and Dijkema R: ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett. 392:49–53. 1996.

Dixon D, Couse JF and Korach KS: Disruption of the estrogen receptor gene in mice. Toxicol Pathol. 25:518–520. 1997. View Article : Google Scholar : PubMed/NCBI

Elliston JF, Fawell SE, Klein-Hitpass L, et al: Mechanism of estrogen receptor-dependent transcription in a cell-free system. Mol Cell Biol. 10:6607–6612. 1990.PubMed/NCBI

Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR and Katzenellenbogen BS: Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology. 144:4562–4574. 2003. View Article : Google Scholar : PubMed/NCBI

Webb P, Lopez GN, Uht RM and Kushner PJ: Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol. 9:443–456. 1995.PubMed/NCBI

Kushner PJ, Agard DA, Greene GL, et al: Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol. 74:311–317. 2000. View Article : Google Scholar : PubMed/NCBI

Smith CL and O’Malley BW: Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev. 25:45–71. 2004. View Article : Google Scholar : PubMed/NCBI

Osborne CK, Bardou V, Hopp TA, et al: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 95:353–361. 2003. View Article : Google Scholar : PubMed/NCBI

Saville B, Wormke M, Wang F, et al: Ligand-, cell-, and estrogen receptor subtype (α/β)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem. 275:5379–5387. 2000.

Kelloff GJ, Lippman SM, Dannenberg AJ, et al: Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - a plan to move forward. Clin Cancer Res. 12:3661–3697. 2006. View Article : Google Scholar : PubMed/NCBI

Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK and Osborne CK: Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res. 10:331S–336S. 2004. View Article : Google Scholar : PubMed/NCBI

Le Goff P, Montano MM, Schodin DJ and Katzenellenbogen BS: Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem. 269:4458–4466. 1994.PubMed/NCBI

Vyhlidal C, Samudio I, Kladde MP and Safe S: Transcriptional activation of transforming growth factor α by estradiol: requirement for both a GC-rich site and an estrogen response element half-site. J Mol Endocrinol. 24:329–338. 2000.

Lee AV, Cui X and Oesterreich S: Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res. 7(Suppl 12): S4429–S4435. 2001.PubMed/NCBI

Yarden RI, Wilson MA and Chrysogelos SA: Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J Cell Biochem. (Suppl 36): 232–246. 2001. View Article : Google Scholar : PubMed/NCBI

Bayliss J, Hilger A, Vishnu P, Diehl K and El-Ashry D: Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clin Cancer Res. 13:7029–7036. 2007. View Article : Google Scholar : PubMed/NCBI

Cui X, Zhang P, Deng W, et al: Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3–kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol. 17:575–588. 2003.PubMed/NCBI

Brinkman JA and El-Ashry D: ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers. J Mammary Gland Biol Neoplasia. 14:67–78. 2009. View Article : Google Scholar : PubMed/NCBI

Levin ER and Pietras RJ: Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat. 108:351–361. 2008. View Article : Google Scholar : PubMed/NCBI

Pedram A, Razandi M, Lubahn D, Liu J, Vannan M and Levin ER: Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-β to inhibit calcineurin. Endocrinology. 149:3361–3369. 2008.PubMed/NCBI

Wu RC, Qin J, Yi P, et al: Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol Cell. 15:937–949. 2004. View Article : Google Scholar : PubMed/NCBI

Pontiggia O, Rodriguez V, Fabris V, et al: Establishment of an in vitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal-epithelial interactions. Breast Cancer Res Treat. 116:247–255. 2009. View Article : Google Scholar

Machuca TN, Hsin MK, Ott HC, et al: Injury-specific ex vivo treatment of the donor lung: pulmonary thrombolysis followed by successful lung transplantation. Am J Respir Crit Care Med. 188:878–880. 2013. View Article : Google Scholar : PubMed/NCBI

Goetz MP, Rae JM, Suman VJ, et al: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 23:9312–9318. 2005. View Article : Google Scholar : PubMed/NCBI

Stearns V and Rae JM: Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response? Expert Rev Mol Med. 10:e342008. View Article : Google Scholar : PubMed/NCBI

Jaiswal BS, Janakiraman V, Kljavin NM, et al: Somatic mutations in p85α promote tumorigenesis through class IA PI3K activation. Cancer Cell. 16:463–474. 2009.

Madeira M, Mattar A, Logullo AF, Soares FA and Gebrim LH: Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer. BMC Cancer. 13:4252013. View Article : Google Scholar

McGuire WL: Current status of estrogen receptors in human breast cancer. Cancer. 36:638–644. 1975. View Article : Google Scholar : PubMed/NCBI

Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, et al: Estrogen receptor β (ERβ) level but not its ERβcx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res. 10:5769–5776. 2004.

Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK and Fuqua SA: Low levels of estrogen receptor β protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res. 10:7490–7499. 2004.

Kuiper GG, Lemmen JG, Carlsson B, et al: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology. 139:4252–4263. 1998.

Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG and Davidson NE: Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells. Cancer Res. 61:7025–7029. 2001.

Parl FF: Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer. Pharmacogenomics J. 3:251–253. 2003. View Article : Google Scholar : PubMed/NCBI

Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB and Davidson NE: Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 54:2552–2555. 1994.PubMed/NCBI

Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL and Wolffe AP: DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet. 25:338–342. 2000. View Article : Google Scholar : PubMed/NCBI

Fan J, Yin WJ, Lu JS, et al: ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J Cancer Res Clin Oncol. 134:883–890. 2008.

Zhou Q, Shaw PG and Davidson NE: Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. Breast Cancer Res Treat. 117:443–451. 2009. View Article : Google Scholar : PubMed/NCBI

Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S and Brodie AM: Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res. 71:1893–1903. 2011.

Mahfoudi A, Roulet E, Dauvois S, Parker MG and Wahli W: Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA. 92:4206–4210. 1995. View Article : Google Scholar : PubMed/NCBI

Wolf DM and Jordan VC: The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat. 31:129–138. 1994. View Article : Google Scholar : PubMed/NCBI

MacGregor Schafer J, Liu H, Bentrem DJ, Zapf JW and Jordan VC: Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res. 60:5097–5105. 2000.

Thomas RS, Sarwar N, Phoenix F, Coombes RC and Ali S: Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-α activity. J Mol Endocrinol. 40:173–184. 2008.PubMed/NCBI

Chen D, Washbrook E, Sarwar N, et al: Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene. 21:4921–4931. 2002.

Williams CC, Basu A, El-Gharbawy A, Carrier LM, Smith CL and Rowan BG: Identification of four novel phosphorylation sites in estrogen receptor α: impact on receptor-dependent gene expression and phosphorylation by protein kinase CK2. BMC Biochem. 10:362009.PubMed/NCBI

Rogatsky I, Trowbridge JM and Garabedian MJ: Potentiation of human estrogen receptor α transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J Biol Chem. 274:22296–22302. 1999.

Michalides R, van Tinteren H, Balkenende A, et al: Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer. 86:402–408. 2002. View Article : Google Scholar : PubMed/NCBI

Vendrell JA, Bieche I, Desmetz C, et al: Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines. Endocr Relat Cancer. 12:75–92. 2005. View Article : Google Scholar

Likhite VS, Stossi F, Kim K, Katzenellenbogen BS and Katzenellenbogen JA: Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol. 20:3120–3132. 2006. View Article : Google Scholar

Kato S, Endoh H, Masuhiro Y, et al: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 270:1491–1494. 1995. View Article : Google Scholar : PubMed/NCBI

Barone I, Brusco L and Fuqua SA: Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res. 16:2702–2708. 2010. View Article : Google Scholar : PubMed/NCBI

de Leeuw R, Neefjes J and Michalides R: A role for estrogen receptor phosphorylation in the resistance to tamoxifen. Int J Breast Cancer. 2011:2324352011.PubMed/NCBI

Osborne CK and Schiff R: Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol. 23:1616–1622. 2005. View Article : Google Scholar : PubMed/NCBI

Girault I, Bièche I and Lidereau R: Role of estrogen receptor α transcriptional coregulators in tamoxifen resistance in breast cancer. Maturitas. 54:342–351. 2006.

Webb P, Nguyen P, Shinsako J, et al: Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol Endocrinol. 12:1605–1618. 1998. View Article : Google Scholar : PubMed/NCBI

Kressler D, Hock MB and Kralli A: Coactivators PGC-1β and SRC-1 interact functionally to promote the agonist activity of the selective estrogen receptor modulator tamoxifen. J Biol Chem. 282:26897–26907. 2007.

Fuqua SA, Schiff R, Parra I, et al: Estrogen receptor β protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res. 63:2434–2439. 2003.

Lavinsky RM, Jepsen K, Heinzel T, et al: Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA. 95:2920–2925. 1998. View Article : Google Scholar : PubMed/NCBI

Kurokawa H, Lenferink AE, Simpson JF, et al: Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 60:5887–5894. 2000.

Massarweh S, Osborne CK, Creighton CJ, et al: Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 68:826–833. 2008. View Article : Google Scholar : PubMed/NCBI

Fagan DH, Uselman RR, Sachdev D and Yee D: Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res. 72:3372–3380. 2012. View Article : Google Scholar : PubMed/NCBI

Ciampolillo A, De Tullio C and Giorgino F: The IGF-I/IGF-I receptor pathway: implications in the pathophysiology of thyroid cancer. Curr Med Chem. 12:2881–2891. 2005. View Article : Google Scholar : PubMed/NCBI

Lee AV, Weng CN, Jackson JG and Yee D: Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol. 152:39–47. 1997. View Article : Google Scholar : PubMed/NCBI

Fagan DH and Yee D: Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia. 13:423–429. 2008. View Article : Google Scholar : PubMed/NCBI

Lee AV, Darbre P and King RJ: Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells. Mol Cell Endocrinol. 99:211–220. 1994. View Article : Google Scholar : PubMed/NCBI

Umayahara Y, Kawamori R, Watada H, et al: Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J Biol Chem. 269:16433–16442. 1994.PubMed/NCBI

Salerno M, Sisci D, Mauro L, Guvakova MA, Ando S and Surmacz E: Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells. Int J Cancer. 81:299–304. 1999. View Article : Google Scholar : PubMed/NCBI

Becker MA, Ibrahim YH, Cui X, Lee AV and Yee D: The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol. 25:516–528. 2011.

Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S and Nakshatri H: Phosphatidylinositol 3-kinase/AKT- mediated activation of estrogen receptor α: a new model for anti-estrogen resistance. J Biol Chem. 276:9817–9824. 2001.

Ahn BY, Elwi AN, Lee B, et al: Genetic screen identifies insulin-like growth factor binding protein 5 as a modulator of tamoxifen resistance in breast cancer. Cancer Res. 70:3013–3019. 2010. View Article : Google Scholar : PubMed/NCBI

Beattie J, Allan GJ, Lochrie JD and Flint DJ: Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J. 395:1–19. 2006. View Article : Google Scholar : PubMed/NCBI

Akkiprik M, Feng Y, Wang H, et al: Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer. Breast Cancer Res. 10:2122008. View Article : Google Scholar : PubMed/NCBI

Bunone G, Briand PA, Miksicek RJ and Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15:2174–2183. 1996.PubMed/NCBI

Parisot JP, Hu XF, DeLuise M and Zalcberg JR: Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br J Cancer. 79:693–700. 1999. View Article : Google Scholar : PubMed/NCBI

Knowlden JM, Hutcheson IR, Barrow D, Gee JM and Nicholson RI: Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology. 146:4609–4618. 2005. View Article : Google Scholar : PubMed/NCBI

Cohen BD, Baker DA, Soderstrom C, et al: Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res. 11:2063–2073. 2005. View Article : Google Scholar : PubMed/NCBI

Lu Y, Zi X, Zhao Y, Mascarenhas D and Pollak M: Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 93:1852–1857. 2001. View Article : Google Scholar : PubMed/NCBI

Bouton AH, Riggins RB and Bruce-Staskal PJ: Functions of the adapter protein Cas: signal convergence and the determination of cellular responses. Oncogene. 20:6448–6458. 2001. View Article : Google Scholar : PubMed/NCBI

Defilippi P, Di Stefano P and Cabodi S: p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol. 16:257–263. 2006. View Article : Google Scholar : PubMed/NCBI

Lu Y, Mani S, Kandimalla ER, et al: The Cockayne syndrome group B DNA repair protein as an anti-cancer target. Int J Oncol. 19:1089–1097. 2001.PubMed/NCBI

Planas-Silva MD and Hamilton KN: Targeting c-Src kinase enhances tamoxifen’s inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins. Cancer Chemother Pharmacol. 60:535–543. 2007.PubMed/NCBI

Schuh NR, Guerrero MS, Schrecengost RS and Bouton AH: BCAR3 regulates Src/p130 Cas association, Src kinase activity, and breast cancer adhesion signaling. J Biol Chem. 285:2309–2317. 2010. View Article : Google Scholar : PubMed/NCBI

Gotoh T, Cai D, Tian X, Feig LA and Lerner A: p130^Cas regulates the activity of AND-34, a novel Ral, Rap1, and R-Ras guanine nucleotide exchange factor. J Biol Chem. 275:30118–30123. 2000.

Cai D, Iyer A, Felekkis KN, et al: AND-34/BCAR3, a GDP exchange factor whose overexpression confers antiestrogen resistance, activates Rac, PAK1, and the cyclin D1 promoter. Cancer Res. 63:6802–6808. 2003.PubMed/NCBI

van Agthoven T, van Agthoven TL, Dekker A, van der Spek PJ, Vreede L and Dorssers LC: Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J. 17:2799–2808. 1998.PubMed/NCBI

Felekkis KN, Narsimhan RP, Near R, et al: AND-34 activates phosphatidylinositol 3-kinase and induces anti-estrogen resistance in a SH2 and GDP exchange factor-like domain-dependent manner. Mol Cancer Res. 3:32–41. 2005.PubMed/NCBI

Liu P, Cheng H, Roberts TM and Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 8:627–644. 2009. View Article : Google Scholar : PubMed/NCBI

Miller TW, Balko JM and Arteaga CL: Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 29:4452–4461. 2011. View Article : Google Scholar : PubMed/NCBI

Fox EM, Arteaga CL and Miller TW: Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer. Front Oncol. 2:1452012.

Turner N, Pearson A, Sharpe R, et al: FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 70:2085–2094. 2010. View Article : Google Scholar

van der Kaay J, Cullen PJ and Downes CP: Phosphatidylinositol(3,4,5)trisphosphate (Ptdins(3,4,5)P₃) mass measurement using a radioligand displacement assay. Methods Mol Biol. 105:109–125. 1998.

Maehama T and Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 273:13375–13378. 1998. View Article : Google Scholar : PubMed/NCBI

Massarweh S and Schiff R: Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res. 13:1950–1954. 2007. View Article : Google Scholar : PubMed/NCBI

Lewis-Wambi JS and Jordan VC: Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res. 11:2062009. View Article : Google Scholar : PubMed/NCBI

Schiff R, Reddy P, Ahotupa M, et al: Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 92:1926–1934. 2000. View Article : Google Scholar : PubMed/NCBI

Nair BC and Vadlamudi RK: Regulation of hormonal therapy resistance by cell cycle machinery. Gene Ther Mol Biol. 12:3952008.PubMed/NCBI

Butt AJ, McNeil CM, Musgrove EA and Sutherland RL: Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer. 12(Suppl 10): S47–S59. 2005. View Article : Google Scholar : PubMed/NCBI

Kilker RL, Hartl MW, Rutherford TM and Planas-Silva MD: Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells. J Steroid Biochem Mol Biol. 92:63–71. 2004. View Article : Google Scholar : PubMed/NCBI

Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R and Michalides RJ: CDK-independent activation of estrogen receptor by cyclin D1. Cell. 88:405–415. 1997. View Article : Google Scholar : PubMed/NCBI

Wilcken NR, Prall OW, Musgrove EA and Sutherland RL: Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin Cancer Res. 3:849–854. 1997.PubMed/NCBI

Osborne CK and Schiff R: Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast. 12:362–367. 2003. View Article : Google Scholar : PubMed/NCBI

Rudas M, Lehnert M, Huynh A, et al: Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin Cancer Res. 14:1767–1774. 2008. View Article : Google Scholar : PubMed/NCBI

Stendahl M, Kronblad A, Rydén L, Emdin S, Bengtsson NO and Landberg G: Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer. 90:1942–1948. 2004. View Article : Google Scholar : PubMed/NCBI

Sieuwerts AM, Look MP, Meijer-van Gelder ME, et al: Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin Cancer Res. 12:3319–3328. 2006. View Article : Google Scholar : PubMed/NCBI

Bosco EE, Wang Y, Xu H, et al: The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest. 117:218–228. 2007. View Article : Google Scholar : PubMed/NCBI

Musgrove EA, Sergio CM, Anderson LR, et al: Identification of downstream targets of estrogen and c-myc in breast cancer cells. Adv Exp Med Biol. 617:445–451. 2008. View Article : Google Scholar : PubMed/NCBI

Dhillon NK and Mudryj M: Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest. Oncogene. 21:4626–4634. 2002. View Article : Google Scholar : PubMed/NCBI

Hui R, Finney GL, Carroll JS, Lee CS, Musgrove EA and Sutherland RL: Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res. 62:6916–6923. 2002.PubMed/NCBI

Caldon CE, Sergio CM, Schütte J, et al: Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc. Mol Cell Biol. 29:4623–4639. 2009. View Article : Google Scholar : PubMed/NCBI

Finn RS, Dering J, Conklin D, et al: PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 11:R772009. View Article : Google Scholar

Wang L, Wang J, Blaser BW, et al: Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood. 110:2075–2083. 2007. View Article : Google Scholar : PubMed/NCBI

Planas-Silva MD and Weinberg RA: Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol. 17:4059–4069. 1997.PubMed/NCBI

Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N and Slingerland JM: Down-regulation of p21^WAF1/CIP1 or p27^Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci USA. 97:9042–9046. 2000.PubMed/NCBI

Bachman KE, Blair BG, Brenner K, et al: p21^WAF1/CIP1 mediates the growth response to TGF-β in human epithelial cells. Cancer Biol Ther. 3:221–225. 2004.

Mokbel K: The evolving role of aromatase inhibitors in breast cancer. Int J Clin Oncol. 7:279–283. 2002.PubMed/NCBI

Jordan VC: Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol. 147(Suppl 1): S269–S276. 2006. View Article : Google Scholar : PubMed/NCBI

Pohl G, Rudas M, Dietze O, et al: High p27^Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. J Clin Oncol. 21:3594–3600. 2003.

Abukhdeir AM and Park BH: P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med. 10:e192008. View Article : Google Scholar : PubMed/NCBI

Ellis PA, Smith IE, Detre S, et al: Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat. 48:107–116. 1998. View Article : Google Scholar : PubMed/NCBI

Cannings E, Kirkegaard T, Tovey SM, Dunne B, Cooke TG and Bartlett JM: Bad expression predicts outcome in patients treated with tamoxifen. Breast Cancer Res Treat. 102:173–179. 2007. View Article : Google Scholar : PubMed/NCBI

Hur J, Chesnes J, Coser KR, et al: The Bik BH3-only protein is induced in estrogen-starved and antiestrogen-exposed breast cancer cells and provokes apoptosis. Proc Natl Acad Sci USA. 101:2351–2356. 2004. View Article : Google Scholar : PubMed/NCBI

Fu Y, Li J and Lee AS: GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis. Cancer Res. 67:3734–3740. 2007. View Article : Google Scholar

Viedma-Rodriguez R, Baiza-Gutman LA, García-Carrancá A, Moreno-Fierros L, Salamanca-Gómez F and Arenas-Aranda D: Suppression of the death gene BIK is a critical factor for resistance to tamoxifen in MCF-7 breast cancer cells. Int J Oncol. 43:1777–1786. 2013.PubMed/NCBI

Lopez J, Hesling C, Prudent J, et al: Src tyrosine kinase inhibits apoptosis through the Erk1/2-dependent degradation of the death accelerator Bik. Cell Death Differ. 19:1459–1469. 2012. View Article : Google Scholar : PubMed/NCBI

Schoenlein PV, Periyasamy-Thandavan S, Samaddar JS, Jackson WH and Barrett JT: Autophagy facilitates the progression of ERα-positive breast cancer cells to antiestrogen resistance. Autophagy. 5:400–403. 2009.

Galluzzi L, Vicencio JM, Kepp O, Tasdemir E, Maiuri MC and Kroemer G: To die or not to die: that is the autophagic question. Curr Mol Med. 8:78–91. 2008. View Article : Google Scholar : PubMed/NCBI

Cully M, You H, Levine AJ and Mak TW: Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 6:184–192. 2006. View Article : Google Scholar : PubMed/NCBI

Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 441:424–430. 2006. View Article : Google Scholar : PubMed/NCBI

Degenhardt K, Mathew R, Beaudoin B, et al: Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell. 10:51–64. 2006. View Article : Google Scholar : PubMed/NCBI

Feng W, Huang S, Wu H and Zhang M: Molecular basis of Bcl-xL’s target recognition versatility revealed by the structure of Bcl-xL in complex with the BH3 domain of Beclin-1. J Mol Biol. 372:223–235. 2007.

Ciechomska IA, Goemans GC, Skepper JN and Tolkovsky AM: Bcl-2 complexed with Beclin-1 maintains full anti-apoptotic function. Oncogene. 28:2128–2141. 2009. View Article : Google Scholar : PubMed/NCBI

Maiuri MC, Le Toumelin G, Criollo A, et al: Functional and physical interaction between Bcl-X_L and a BH3-like domain in Beclin-1. EMBO J. 26:2527–2539. 2007. View Article : Google Scholar : PubMed/NCBI

Levine B, Sinha S and Kroemer G: Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy. 4:600–606. 2008. View Article : Google Scholar : PubMed/NCBI

Boyd JM, Gallo GJ, Elangovan B, et al: Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene. 11:1921–1928. 1995.PubMed/NCBI

Naumann U, Bähr O, Wolburg H, et al: Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice. Gene Ther. 14:147–161. 2007. View Article : Google Scholar : PubMed/NCBI

Oppermann M, Geilen CC, Fecker LF, Gillissen B, Daniel PT and Eberle J: Caspase-independent induction of apoptosis in human melanoma cells by the proapoptotic Bcl-2-related protein Nbk/Bik. Oncogene. 24:7369–7380. 2005. View Article : Google Scholar : PubMed/NCBI

Garcia N, Salamanca F, Astudillo-de la Vega H, et al: A molecular analysis by gene expression profiling reveals Bik/NBK overexpression in sporadic breast tumor samples of Mexican females. BMC Cancer. 5:932005. View Article : Google Scholar : PubMed/NCBI

Hirsch DS, Shen Y, Dokmanovic M and Wu WJ: pp60^c-Src phosphorylates and activates vacuolar protein sorting 34 to mediate cellular transformation. Cancer Res. 70:5974–5983. 2010.

Gao P, Bauvy C, Souquère S, et al: The Bcl-2 homology domain 3 mimetic gossypol induces both Beclin 1-dependent and Beclin 1-independent cytoprotective autophagy in cancer cells. J Biol Chem. 285:25570–25581. 2010. View Article : Google Scholar : PubMed/NCBI

Furuya N, Yu J, Byfield M, Pattingre S and Levine B: The evolutionarily conserved domain of Beclin 1 is required for Vps34 binding, autophagy and tumor suppressor function. Autophagy. 1:46–52. 2005. View Article : Google Scholar : PubMed/NCBI

Musgrove EA and Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 9:631–643. 2009. View Article : Google Scholar : PubMed/NCBI

Dancey J: mTOR signaling and drug development in cancer. Nat Rev Clin Oncol. 7:209–219. 2010. View Article : Google Scholar : PubMed/NCBI

Ciafrè SA, Galardi S, Mangiola A, et al: Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 334:1351–1358. 2005.PubMed/NCBI

Pallante P, Visone R, Ferracin M, et al: MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer. 13:497–508. 2006. View Article : Google Scholar : PubMed/NCBI

Kondo N, Toyama T, Sugiura H, Fujii Y and Yamashita H: miR-206 expression is down-regulated in estrogen receptor α-positive human breast cancer. Cancer Res. 68:5004–5008. 2008.

Rao X, Di Leva G, Li M, et al: MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 30:1082–1097. 2011. View Article : Google Scholar : PubMed/NCBI

Sachdeva M, Wu H, Ru P, Hwang L, Trieu V and Mo YY: MicroRNA-101-mediated Akt activation and estrogen-independent growth. Oncogene. 30:822–831. 2011. View Article : Google Scholar : PubMed/NCBI

Miller TE, Ghoshal K, Ramaswamy B, et al: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27^Kip1. J Biol Chem. 283:29897–29903. 2008. View Article : Google Scholar : PubMed/NCBI

Kovalchuk O, Filkowski J, Meservy J, et al: Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther. 7:2152–2159. 2008. View Article : Google Scholar : PubMed/NCBI

Liang Z, Wu H, Xia J, et al: Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol. 79:817–824. 2010. View Article : Google Scholar

Xin F, Li M, Balch C, et al: Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics. 25:430–434. 2009. View Article : Google Scholar

Guardavaccaro D and Clevers H: Wnt/β-catenin and MAPK signaling: allies and enemies in different battlefields. Sci Signal. 5:pe152012.

Gabrovska PN, Smith RA, Tiang T, Weinstein SR, Haupt LM and Griffiths LR: Development of an eight gene expression profile implicating human breast tumours of all grade. Mol Biol Rep. 39:3879–3892. 2012. View Article : Google Scholar

Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI and Goss KH: Wnt/β-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 176:2911–2920. 2010.

Loh YN, Hedditch EL, Baker LA, Jary E, Ward RL and Ford CE: The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. BMC Cancer. 13:1742013. View Article : Google Scholar : PubMed/NCBI

Katoh M: Comparative genomics on Wnt3-Wnt9b gene cluster. Int J Mol Med. 15:743–747. 2005.PubMed/NCBI

Rubin JS, Bottaro DP, Chedid M, et al: Keratinocyte growth factor. Cell Biol Int. 19:399–411. 1995. View Article : Google Scholar

Rubin JS, Bottaro DP, Chedid M, et al: Keratinocyte growth factor as a cytokine that mediates mesenchymal-epithelial interaction. EXS. 74:191–214. 1995.PubMed/NCBI

Kumar V, Green S, Staub A and Chambon P: Localisation of the oestradiol-binding and putative DNA-binding domains of the human oestrogen receptor. EMBO J. 5:2231–2236. 1986.PubMed/NCBI

Berry M, Metzger D and Chambon P: Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 9:2811–2818. 1990.

Mader S, Chambon P and White JH: Defining a minimal estrogen receptor DNA binding domain. Nucleic Acids Res. 21:1125–1132. 1993. View Article : Google Scholar : PubMed/NCBI

Wang Z, Li Y, Banerjee S and Sarkar FH: Emerging role of Notch in stem cells and cancer. Cancer Lett. 279:8–12. 2009. View Article : Google Scholar : PubMed/NCBI

Shi TP, Xu H, Wei JF, et al: Association of low expression of notch-1 and jagged-1 in human papillary bladder cancer and shorter survival. J Urol. 180:361–366. 2008. View Article : Google Scholar : PubMed/NCBI

Al Saleh S, Sharaf LH and Luqmani YA: Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review). Int J Oncol. 38:1197–1217. 2011.PubMed/NCBI

Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM and Wicha MS: Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 6:R605–R615. 2004. View Article : Google Scholar : PubMed/NCBI

Stylianou S, Clarke RB and Brennan K: Aberrant activation of notch signaling in human breast cancer. Cancer Res. 66:1517–1525. 2006. View Article : Google Scholar : PubMed/NCBI

Rizzo P, Miao H, D’Souza G, et al: Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res. 68:5226–5235. 2008. View Article : Google Scholar : PubMed/NCBI

Wang Z, Li Y, Ahmad A, et al: Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta. 1806:258–267. 2010.PubMed/NCBI

Hurvitz SA and Pietras RJ: Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer. 113:2385–2397. 2008. View Article : Google Scholar

Dibb NJ, Dilworth SM and Mol CD: Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat Rev Cancer. 4:718–727. 2004. View Article : Google Scholar : PubMed/NCBI

Weigel MT, Ghazoui Z, Dunbier A, Pancholi S, Dowsett M and Martin LA: Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. Breast Cancer Res. 14:R782012. View Article : Google Scholar

Pancholi V: Multifunctional α-enolase: its role in diseases. Cell Mol Life Sci. 58:902–920. 2001.

Jiang BH, Agani F, Passaniti A and Semenza GL: V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 57:5328–5335. 1997.

Wygrecka M, Marsh LM, Morty RE, et al: Enolase-1 promotes plasminogen-mediated recruitment of monocytes to the acutely inflamed lung. Blood. 113:5588–5598. 2009. View Article : Google Scholar : PubMed/NCBI

Dudani AK, Cummings C, Hashemi S and Ganz PR: Isolation of a novel 45 kDa plasminogen receptor from human endothelial cells. Thromb Res. 69:185–196. 1993. View Article : Google Scholar : PubMed/NCBI

Peebles KA, Duncan MW, Ruch RJ and Malkinson AM: Proteomic analysis of a neoplastic mouse lung epithelial cell line whose tumorigenicity has been abrogated by transfection with the gap junction structural gene for connexin 43, Gja1. Carcinogenesis. 24:651–657. 2003. View Article : Google Scholar

Wu W, Tang X, Hu W, Lotan R, Hong WK and Mao L: Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis. 19:319–326. 2002. View Article : Google Scholar : PubMed/NCBI

Ray R and Miller DM: Cloning and characterization of a human c-myc promoter-binding protein. Mol Cell Biol. 11:2154–2161. 1991.PubMed/NCBI

Tu SH, Chang CC, Chen CS, et al: Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 121:539–553. 2010.